Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company granted Medicinal Cannabis Licence

Canndeo Ltd operates under a pharmaceutical model.
The Hydroponics Company granted Medicinal Cannabis Licence
THC's shares have opened higher

The Hydroponics Company Ltd's (ASX:THC) shares have jumped 29% in morning trade following the company's  subsidiary, Canndeo Ltd, being granted a Medicinal Cannabis Licence by the Office of Drug Control that authorises the cultivation and growth of cannabis plants for medicinal purposes.

Obtaining the licence meets one of Canndeo’s key milestones on the path to its goal – the commercial cultivation of medicinal cannabis in Australia.

This is the second of three licences approved, with the company having lodged a manufacturing licence and is awaiting approval.

Canndeo operates under a pharmaceutical model with a focus on the end-to-end supply of medicinal cannabis products.

THC is continuing to pursue a dual supply strategy intended to give it the capacity and capability to meet market demand with product it manufactures in Australia as well as imported products.

Details of the license

The Australian Government’s Office of Drug Control issued to Canndeo Ltd, a Medicinal Cannabis Licence for the growth and cultivation of cannabis plants under the medicinal cannabis provisions of the Narcotic Drugs Act 1967.

The licence is an important step along the path towards the company achieving its goal of establishing a legal domestic source of cannabis for medicinal use in Australia.

It also puts the THC Group amongst only a few companies to have two licences granted by The Office of Drug Control.

David Radford, chief executive officer for THC, commented:

"This licence is a major milestone in the company’s objective to supply high quality medicinal cannabis products from both local and international sources to the Australian patient groups.

"The issuing of this licence supports the strategic growth plan which, as advised in the recently released quarterly, is focused upon a build out of the existing Canadian business and an accelerated path to market for medicinal cannabis in Australia.

"It is a major step in the transition of the company towards commercial supply and monetisation of the opportunity that exists in the medicinal cannabis market and I congratulate the team for their diligent efforts in achieving this licence."

THC's plans in Canada

The Canadian market, following legalisation of cannabis for adult use, which is expected to take place in July 2018, is estimated to grow annually to a $5-10 billion local market.

THC’s wholly owned subsidiaries, Crystal Mountain Dragon Vision (CMDV), are primarily focused on serving this market.

CMDV is aiming to service the current larger licenced producers that have already commenced significant cropping and production of medical cannabis and the additional ones that will come online in the near future, as well as expanding its network of retail store customers internationally.

THC is therefore gaining exposure to one of the fastest growing cannabis markets in the world through its continued investment in the Canadian.

View full THC profile View Profile

The Hydroponics Company Timeline

Related Articles

Picture of evolis products
April 04 2018
Fillerina® is complementary to the company’s evolis® haircare range.
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
test tubes
January 23 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use